Comparative Pharmacology
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL versus OGEN 2 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL versus OGEN 2 5.
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL vs OGEN 2.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; levonorgestrel alters cervical mucus and endometrial lining to prevent fertilization and implantation.
Estrogen replacement therapy; binds to estrogen receptors, leading to activation of estrogen-responsive genes and physiological effects mimicking endogenous estrogens.
One tablet containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol (or 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo or ethinyl estradiol 0.01 mg alone. For extended-cycle regimens, dosing may be continuous for up to 84 days.
0.625 mg orally once daily (estropipate 0.75 mg equivalent), cyclic or continuous.
None Documented
None Documented
Levonorgestrel: ~25 hours; Ethinyl estradiol: ~13 hours. Steady-state achieved within 5-7 days; clinical efficacy maintained by daily dosing.
10-24 hours; terminal half-life may be prolonged in hepatic impairment.
Levonorgestrel: 45% renal, 32% fecal; Ethinyl estradiol: 40% renal, 60% fecal. Both undergo enterohepatic recirculation.
Primarily renal as sulfate and glucuronide conjugates; less than 10% excreted unchanged.
Category D/X
Category C
Estrogen
Estrogen